Literature DB >> 21134601

Tuning of lipophilicity and cytotoxic potency by structural variation of anticancer platinum(IV) complexes.

Michael R Reithofer1, Anna K Bytzek, Seied M Valiahdi, Christian R Kowol, Michael Groessl, Christian G Hartinger, Michael A Jakupec, Markus Galanski, Bernhard K Keppler.   

Abstract

A series of bis(carboxylato)dichlorido(ethane-1,2-diamine)platinum(IV) compounds with IC(50) values ranging between 142 μM and 18 nM was investigated with respect to their lipophilicity (by the shake flask method as well as microemulsion electrokinetic chromatography), reduction potential, as well as their cellular accumulation in cancer cells in vitro. In general, the antiproliferative properties of the complexes correlated with their lipophilicity as well as their accumulation, whereas differences in antiproliferative potency could not be explained by reduction potentials since they do not vary significantly within the investigated series of compounds. Only minor effects for complexes featuring polar end groups were detected.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21134601     DOI: 10.1016/j.jinorgbio.2010.09.006

Source DB:  PubMed          Journal:  J Inorg Biochem        ISSN: 0162-0134            Impact factor:   4.155


  21 in total

Review 1.  Synthetic methods for the preparation of platinum anticancer complexes.

Authors:  Justin J Wilson; Stephen J Lippard
Journal:  Chem Rev       Date:  2013-11-27       Impact factor: 60.622

2.  A Family of Rhodium Complexes with Selective Toxicity toward Mismatch Repair-Deficient Cancers.

Authors:  Kelsey M Boyle; Jacqueline K Barton
Journal:  J Am Chem Soc       Date:  2018-04-17       Impact factor: 15.419

3.  Synthesis, characterization, and cytotoxicity of platinum(IV) carbamate complexes.

Authors:  Justin J Wilson; Stephen J Lippard
Journal:  Inorg Chem       Date:  2011-03-01       Impact factor: 5.165

4.  Diamminetetrakis(carboxylato)platinum(IV) complexes--synthesis, characterization, and cytotoxicity.

Authors:  Björn R Hoffmeister; Mahsa S Adib-Razavi; Michael A Jakupec; Markus Galanski; Bernhard K Keppler
Journal:  Chem Biodivers       Date:  2012-09       Impact factor: 2.408

5.  Conjugation of cisplatin analogues and cyclooxygenase inhibitors to overcome cisplatin resistance.

Authors:  Wilma Neumann; Brenda C Crews; Menyhárt B Sárosi; Cristina M Daniel; Kebreab Ghebreselasie; Matthias S Scholz; Lawrence J Marnett; Evamarie Hey-Hawkins
Journal:  ChemMedChem       Date:  2014-10-15       Impact factor: 3.466

6.  Oxidative Reactivity and Cytotoxic Properties of a Platinum(II) Complex Prepared by Outer-Sphere Amide Bond Coupling.

Authors:  Justin J Wilson; Stephen J Lippard
Journal:  Polyhedron       Date:  2013-07-13       Impact factor: 3.052

7.  Effect of reactivity on cellular accumulation and cytotoxicity of oxaliplatin analogues.

Authors:  Irina Buß; Ganna V Kalayda; Andreas Lindauer; Michael R Reithofer; Markus Galanski; Bernhard K Keppler; Ulrich Jaehde
Journal:  J Biol Inorg Chem       Date:  2012-03-29       Impact factor: 3.358

8.  Conjugates of cisplatin and cyclooxygenase inhibitors as potent antitumor agents overcoming cisplatin resistance.

Authors:  Wilma Neumann; Brenda C Crews; Lawrence J Marnett; Evamarie Hey-Hawkins
Journal:  ChemMedChem       Date:  2014-05-06       Impact factor: 3.466

9.  Glutathione-Responsive Prodrug Nanoparticles for Effective Drug Delivery and Cancer Therapy.

Authors:  Xiang Ling; Jiasheng Tu; Junqing Wang; Aram Shajii; Na Kong; Chan Feng; Ye Zhang; Mikyung Yu; Tian Xie; Zameer Bharwani; Bader M Aljaeid; Bingyang Shi; Wei Tao; Omid C Farokhzad
Journal:  ACS Nano       Date:  2018-12-04       Impact factor: 15.881

10.  α(V)β(3) integrin-targeted PLGA-PEG nanoparticles for enhanced anti-tumor efficacy of a Pt(IV) prodrug.

Authors:  Nora Graf; Diane R Bielenberg; Nagesh Kolishetti; Christoph Muus; Jacqueline Banyard; Omid C Farokhzad; Stephen J Lippard
Journal:  ACS Nano       Date:  2012-05-14       Impact factor: 15.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.